Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.61 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.61 |
| ▸ | HTR3B | O95264 | 1/20 | 0.61 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.61 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.61 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.58 |
| ▸ | NCF1 | P14598 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 4/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.47 |
| ▸ | HTR6 | P50406 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3658442 | 0.83 | ALDH1A1 (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL255197 | 0.81 | HTR3A (0.67) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL8707862 | 0.81 | HTR6 (0.54) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL790291 | 0.81 | ALDH1A1 (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL12499570 | 0.80 | IGF1R (0.46) | HTR6MEN1MAPTALOX15ALOX12 | |
| SCHEMBL21808285 | 0.80 | ADRB1 (0.56) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL30641872 | 0.80 | IGF1R (0.46) | HTR6MEN1MAPTALOX15ALOX12 | |
| Hydrochloric Acid SCHEMBL2534803 | 0.80 | HTR3A (0.68) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL30221917 | 0.79 | NCF1 (0.51) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL7057959 | 0.79 | NCF1 (0.51) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| CN-109071560-B | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | 瓦洛健康公司 | 2022-01-14 | — | — | CN | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-06-01 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | HUTCHISON MEDIPHARMA LTD (CN) | 2016-01-07 | — | — | US | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
| WO-2003028728-A1 | 4-(4-SUBSTITUTED PIPERAZINYL-1YL)-BUTYLCARBOXAMIDES AS D3 DOPAMINE SUBTYPE SELECTIVE LIGANDS | Richter Gedeon Vegyészeti Gyár Rt. (HU) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | HTR3A 3030/4885HTR3E 3223/4885HTR3B 3520/4885 |
| US-20160002221-A1 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | HTR3A 1424/4885HTR3E 1618/4885HTR3B 1466/4885 |
| US-20170152258-A9 | Substituted Pyridopyrazines as Syk Inhibitors | SYK, BTK, LYN | HTR3A 1424/4885HTR3E 1618/4885HTR3B 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.